| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.11 | 0.006 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.098 | 0.006 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.19 | 0.007 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.008 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.21 | 0.008 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |